{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transplant+Ineligible&page=2", "query": { "condition": "Transplant Ineligible", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transplant+Ineligible&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T01:01:09.055Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01782963", "title": "Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 50, "start_date": "2013-03", "completion_date": "2017-12", "has_results": true, "last_update_posted_date": "2018-10-31", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 6, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Danvers, Massachusetts", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01782963" }, { "nct_id": "NCT02775903", "title": "An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 213, "start_date": "2016-06-03", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2023-02-28", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02775903" }, { "nct_id": "NCT03138499", "title": "A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hodgkin's Disease" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Brentuximab vedotin", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2017-06-26", "completion_date": "2021-02-22", "has_results": true, "last_update_posted_date": "2024-01-10", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 20, "location_summary": "Duarte, California • Long Beach, California • Los Angeles, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138499" }, { "nct_id": "NCT01818752", "title": "Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 955, "start_date": "2013-07-08", "completion_date": "2016-11-04", "has_results": true, "last_update_posted_date": "2019-08-26", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 14, "location_summary": "Fresno, California • Greenbrae, California • Modesto, California + 11 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01818752" }, { "nct_id": "NCT04009109", "title": "Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma, Multiple" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Daratumumab Injection", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 79, "start_date": "2020-10-21", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 7, "location_summary": "Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more", "locations": [ { "city": "Bangor", "state": "Maine" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04009109" }, { "nct_id": "NCT04990102", "title": "Phase IB/II of CPX-351 for Relapse Prevention in AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML) in Remission" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2023-05-22", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • Hackensack, New Jersey • Philadelphia, Pennsylvania", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990102" }, { "nct_id": "NCT01078454", "title": "Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Light Chain Deposition Disease", "Primary Systemic Amyloidosis" ], "interventions": [ { "name": "melphalan", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-11", "completion_date": "2012-11-27", "has_results": true, "last_update_posted_date": "2022-02-01", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 209, "location_summary": "Scottsdale, Arizona • Little Rock, Arkansas • Aurora, Colorado + 140 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01078454" }, { "nct_id": "NCT07477587", "title": "A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma (MM)" ], "interventions": [ { "name": "HLX15-SC-Rd", "type": "DRUG" }, { "name": "US-DARZALEX FASPRO®-Rd", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 258, "start_date": "2026-05-27", "completion_date": "2028-02-22", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 9, "location_summary": "Springdale, Arkansas • Jacksonville, Florida • Margate, Florida + 6 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Margate", "state": "Florida" }, { "city": "Ocala", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07477587" }, { "nct_id": "NCT03593915", "title": "A Phase 1b/2 Study of Alvocidib Plus Decitabine or Azacitidine in Patients With MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Alvocidib Plus Decitabine (during dose escalation only) or Azacitidine", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2018-08-29", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2023-11-09", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 12, "location_summary": "Chicago, Illinois • Iowa City, Iowa • Baltimore, Maryland + 9 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03593915" }, { "nct_id": "NCT00800150", "title": "Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "intensity-modulated radiation therapy", "type": "RADIATION" }, { "name": "tomotherapy", "type": "RADIATION" }, { "name": "total marrow irradiation", "type": "RADIATION" }, { "name": "total nodal irradiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 6, "start_date": "2008-11", "completion_date": "2010-10", "has_results": false, "last_update_posted_date": "2015-06-08", "last_synced_at": "2026-06-27T01:01:09.055Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00800150" } ] }